382592-28-1 Usage
Description
1-Methyl-4-[[5-[[[2-(1-Methyl-2-pyrrolidinyl)ethyl]aMino]sulfonyl]-2-propoxybenzoyl]aMino]-3-propyl-1H-pyrazole-5-carboxaMide is a complex organic compound with a unique chemical structure. It is characterized as a brown solid and is primarily used as an intermediate in the synthesis of Udenafil (U250500), a phosphodiesterase 5 inhibitor.
Uses
Used in Pharmaceutical Industry:
1-Methyl-4-[[5-[[[2-(1-Methyl-2-pyrrolidinyl)ethyl]aMino]sulfonyl]-2-propoxybenzoyl]aMino]-3-propyl-1H-pyrazole-5-carboxaMide is used as an intermediate in the preparation of Udenafil (U250500) for the pharmaceutical industry. Udenafil is a phosphodiesterase 5 inhibitor that is utilized in the treatment of erectile dysfunction, improving blood flow to the penis and facilitating an erection in response to sexual stimulation.
As an intermediate, this compound plays a crucial role in the synthesis process of Udenafil, contributing to the development of an effective treatment option for patients suffering from erectile dysfunction. Its unique chemical properties and structure enable it to be a valuable component in the creation of this medication, ultimately benefiting the pharmaceutical industry and those who rely on such treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 382592-28-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,8,2,5,9 and 2 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 382592-28:
(8*3)+(7*8)+(6*2)+(5*5)+(4*9)+(3*2)+(2*2)+(1*8)=171
171 % 10 = 1
So 382592-28-1 is a valid CAS Registry Number.
382592-28-1Relevant articles and documents
PHARMACOLOGICAL COMPOSITION FOR PREVENTION AND TREATMENT OF RESPIRATORY DISEASE CONTAINING PYRAZOLOPYRIMIDINONE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
-
Page/Page column 6, (2010/04/03)
Disclosed herein is composition for prevention and treatment of respiratory disease containing a pyrazolopyrimidinone compound or pharmaceutically acceptable salts thereof as an active ingredient.
AGENT FOR THE PREVENTION AND TREATMENT OF LIVER DISEASES CONTAINING PYRAZOLOPYRIMIDINE DERIVATIVE
-
Page/Page column 7, (2008/06/13)
The present invention relates to the pharmaceutical compositionfor prevention and treatment of liver diseases containing pyrazolopyrimidine derivative as an active ingredient. According to the present invention, pyrazolopyrimidine derivative has an excellent effect on inhibiting collagen synthesis in hepatic stellate cellsand acts directly on the portal vein. Particularly, it may increase the diameter and the amount of blood flow of the portal vein, and finally decrease the pressure thereof. Therefore, pyrazolopyrimidine derivative can be used advantageously for prevention and treatment of hepatic fibrosis, liver cirrhosis caused by hepatic fibrosis, portal hypertension and various complications caused by portal hypertension. In addition, pyrazolopyrimidine derivative according to the present invention can reduce dosing frequency because of its long half-life, and therefore, has an advantage to improve the drug compliance of patients suffering from chronical liver diseases.